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Abstract
Permeability of the endothelial monolayer is increased when
exposed to the bacterial endotoxin LPS. Our previous studies
have shown that heat shock protein (Hsp) 90 inhibitors protect
and restore LPS-mediated hyperpermeability in bovine
pulmonary arterial endothelial cells. In this study, we assessed the
effect of Hsp90 inhibition against LPS-mediated hyperpermeability
in cultured human lung microvascular endothelial cells
(HLMVECs) and delineated the underlying molecular
mechanisms. We demonstrate that Hsp90 inhibition is critical in the
early phase, to prevent LPS-mediated hyperpermeability, and also in
the later phase, to restore LPS-mediated hyperpermeability in
HLMVECs. Because RhoA is a well known mediator of endothelial
hyperpermeability, we investigated the effect of Hsp90 inhibition on
LPS-mediated RhoA signaling. RhoA nitration and activity were
increased by LPS inHLMVECs and suppressedwhen pretreatedwith
the Hsp90 inhibitor, 17-allylamino-17 demethoxy-geldanamycin
(17-AAG). In addition, inhibition of Rho kinase, a downstream
effector of RhoA, protected HLMVECs from LPS-mediated
hyperpermeability and abolished LPS-induced myosin light chain
(MLC) phosphorylation, a target of Rho kinase. In agreement with
these findings, 17-AAGor dominant-negative RhoA attenuated LPS-
induced MLC phosphorylation. MLC phosphorylation induced by
constitutively active RhoA was also suppressed by 17-AAG,
suggesting a role for Hsp90 downstream of RhoA. Inhibition of
Src family kinases also suppressed RhoA activity and MLC
phosphorylation. Together, these data indicate that Hsp90
inhibition prevents and repairs LPS-induced lung endothelial
barrier dysfunction by suppressing Src-mediated RhoA activity
and signaling.
Keywords: endothelial permeability; LPS; heat shock protein 90;
RhoA; Rho kinase
Clinical Relevance
Endothelial hyperpermeability is a serious complication of
acute respiratory distress syndrome. We now present data
revealing a new mechanism regulating endothelial barrier
function, and suggest potential new targets for the prevention
and repair of endothelial hyperpermeability.
The endotoxin LPS, a major component of
the outer membrane of gram-negative
bacteria, is responsible for stimulating
systemic inflammation and vascular
dysfunction (1, 2). LPS binds to the host
Toll-like receptor 4/cluster of differentiation
14/lymphocyte antigen 96 receptor complex
and activates a variety of signaling pathways
(3, 4). Exposure of endothelial cells to LPS
causes vascular hyperpermeability and
potentiates the systemic inflammation that
occurs in acute and chronic diseases, such as
sepsis, atherosclerosis, acute respiratory
distress syndrome, and diabetes.
In endothelial cells, LPS causes
phosphorylation and activation of pp60Src,
a member of the Src family kinase (SFK)
(5). pp60src plays a critical role in LPS-
mediated vascular dysfunction (6, 7).
Activated pp60Src phosphorylates adherens
junction components, such as vascular
endothelial–cadherin, p120 catenin, and
b-catenin, resulting in the disruption of
cell–cell adhesion and increased vascular
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Figure 1. Inhibition of heat shock protein (Hsp) 90 protects and restores the LPS-mediated human lung microvascular endothelial cell (HLMVEC)
hyperpermeability. (A and B) HLMVECs were grown to confluence on electric cell-substrate impedance sensing (ECIS) arrays (8W10E1). Once
a constant resistance was attained, the cells were treated with vehicle, 2 mM 17-allylamino-17 demethoxy-geldanamycin (17-AAG) (A) or 2 mM AUY-922
(B) for 2 hours. LPS (1 EU/ml) was then added as indicated by the arrow, and transendothelial resistance (TER) values were measured continuously.
Resistance was normalized to time = 0 and plotted as a function of time. Data represent means (6 SEM); n = 3 experiments, each performed in triplicate.
*P, 0.01 versus vehicle, #P, 0.01 versus 17-AAG1 LPS and, ##P, 0.01 versus AUY-9221 LPS. C) HLMVECs were added to each insert of a 24-well
millicell culture plate. After 48 hours cells were treated with vehicle or 2 mM AUY-922 for 2 hours. LPS (5 EU/ml) was then added followed by 2M kD
FITC-dextran (1 mg/ml). At 10 hours after LPS addition, 100 ml of basal media was removed, fluorescence intensity was measured and shown relative
to vehicle (100%). Data represent means (6 SEM); n = 3. *P , 0.05 versus vehicle, ##P , 0.05 versus AUY-922 1 LPS. (D and E) Confluent monolayer
was exposed to LPS (1 EU/ml). After 3 hours, 17-AAG (C) or AUY-922 (D) was added to a final concentration of 2 mM. Resistance was normalized to time =
0 and plotted as a function of time. Data represent means (6 SEM); n = 3. *P, 0.01 versus vehicle, #P, 0.01 versus 17-AAG1 LPS and, ##P, 0.01 versus
AUY-922 1 LPS.
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permeability (8). In addition, activation of
pp60Src is a key event in Rho-mediated
signaling (6, 7).
The Rho family of small GTPases plays
an important role in a variety of cellular
responses, including the assembly of
adherens junctions and of cortical actin fibers
(9, 10). RhoA, a member of the Rho family,
is activated by the exchange of GDP for
GTP, and translocates to the plasma
membrane where it stimulates downstream
effectors, such as Rho kinase (ROCK).
ROCK, either directly or indirectly, via
phosphorylation of myosin light chain
(MLC) phosphatase, increases
phosphorylation of MLC (11). MLC
phosphorylation increases actin filament
cross-linking and produces a contractile
force that results in increased vascular
permeability (12, 13).
LPS-induced activation of pp60Src is
attenuated by inhibition of heat shock
protein (Hsp) 90 (5). Hsp90 is a highly
abundant molecular chaperone, essential
for cell growth and survival; it regulates
the function of various proteins that
include several protein kinases, and
transcription factors (14). Inhibition of
Hsp90 using small-molecule inhibitors
have been extensively studied for their
therapeutic potential in targeting cancer
cells and promoting apoptosis (15–17).
A small-molecule inhibitor of Hsp90, 17-
allylamino-17 demethoxy-geldanamycin
(17-AAG), has been tested in preclinical
and early clinical studies in a variety of
solid tumors, and has been shown to
also possess antiangiogenic and anti-
inflammatory activities (18, 19).
We have previously shown that
inhibition of Hsp90 protects and restores
LPS-induced hyperpermeability in bovine
pulmonary arterial endothelial cells
(BPAECs) (5, 20). However, the
underlying mechanisms involved
in this protection by Hsp90 inhibitors
are yet to be determined. In this study
we investigated the mode of action of
17-AAG and NVP-AUY922 (AUY-922),
two well-known Hsp90 inhibitors, in
protecting against LPS-mediated
hyperpermeability of human lung
microvascular endothelial cells
(HLMVECs). Our data show that,
during LPS-induced endothelial
hyperpermeability, Hsp90 inhibitors
preserve endothelial barrier function by




Antibodies against MLC, di-phospho-MLC,
and nitrotyrosine were purchased from Cell
Signaling (Danvers, MA). Anti–b-actin
antibody was purchased from Sigma-
Aldrich (St. Louis, MO) and anti-RhoA
antibody (sc-418) was purchased from
Santa Cruz Biotechnologies (Santa Cruz,
CA). The Hsp90 inhibitor, 17-AAG, was
obtained from the National Cancer
Institute (Bethesda, MD). The Hsp90
inhibitor, AUY-922 (S1069), and the ROCK
inhibitors, Y-27632 (S1049) and
GSK429286 (S1474), were obtained from
Selleck Chemicals (Houston, TX). The SFK
inhibitor, PP2 (1,407), was obtained from
Tocris (Minneapolis, MN).
Adenovirus Construction
Constitutively active (enhanced green
fluorescent protein–RhoA-Q63L; Addgene,
Cambridge, MA) and dominant-negative
(DN) RhoA (enhanced green fluorescent
protein–RhoA-T19N; Addgene) were
subcloned into an adenoviral vector
(Invitrogen, Grand Island, NY).
Replication-deficient adenoviruses
expressing the gene of interest, under the
control of the cytomegalovirus promoter,
were generated in HEK293 cells, purified
using CsCl, titered, and stored in
Dulbecco’s phosphate-buffered saline (PBS)
containing 10% glycerol, 0.5 mmol/L
MgCl2, and 0.5 mmol/L CaCl2 (21, 22).
Adenoviruses for expression of green
fluorescent protein (GFP) and DN Hsp90
(DN-Hsp90) were generated in-house, as
described previously (23).
Cell Culture
HLMVECs were isolated and cultured in-
house as described previously (24).
Assays of Endothelial Permeability
Transendothelial resistance (TER) assay was
performed as described previously (5).
Briefly, roughly 60,000 cells were seeded on
each well of an 8W10E1 electric cell-
substrate impedance sensing (ECIS) array.
After 24 hours, the media were changed
(virus was also added at that time) and
treatments began at 48 hours, when the
resistance was stable between 1,000–1,300
ohms at a frequency of 4,000 Hz and the
capacitance was between 22 and 29
nanofarads. Each experiment was
performed at least in triplicate and repeated
at least three times (n = 3). Resistance was
measured using the ECIS model Zu and
normalized to each well’s value at t = 0.
Paracellular influx across the HLMVEC
monolayer was also studied using the
Transwell assay system in 24-well Millicell
culture plates. A total of 200,000 cells were
seeded apically in each insert and media
were changed after 24 hours. At 48 hours
after seeding, cells were treated with either
vehicle (0.1% dimethyl sulfoxide) or the
Hsp90 inhibitor, AUY-922 (2 mM). After 2
hours, cells were exposed to either PBS or
LPS (5 EU/ml). At 15 minutes after the
addition of LPS, FITC-dextran (2 million
[2M] kD, 1 mg/ml) was added to the apical
media. At 10 hours after LPS addition, 100
ml of basal media was removed and
fluorescence intensity was measured.
RhoA Activity Assay
RhoA activity was determined using a Rho
G-LISA assay kit in accordance with the
manufacturer’s instructions (Cytoskeleton,
Inc., Denver, CO) using HLMVEC cell
lysates. Results were normalized to protein
levels measured by the Precision Red
protein assay reagent.
Animal Studies
Plasmids (40 mg) carrying either DN-Hsp90
cDNA or luciferase cDNA under
cytomegalovirus promoter control were
incubated with the nontoxic jetPEI reagent
(Polyplus Transfection, Inc., New York,
NY) for 15–30 minutes per manufacturer
instructions. The DNA–jetPEI complex was
then injected into male C57BL/6 mice
(7–8 wk of age; Harlan, Indianapolis, IN)
through the tail vein. After 48 hours, LPS
(2 mg/kg) was administered intraperitoneally.
At 24 hours after LPS injection
immunohistochemical staining of
myeloperoxidase and measurement of
Evans blue dye extravasation was
performed as described previously (25). All
animal care and experimental procedures
were approved by the Animal Care




Western blot analyses and
immunoprecipitation experiments were
performed as described previously (5, 20).
Densitometry was performed using
Imagequant 5.1 (GE Healthcare Bio-
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Sciences, Pittsburgh, PA) and plotted as
fold change from vehicle.
Statistical Analyses
Data are presented as mean values (6 SEM).
Comparisons among groups were
performed using either one-way or two-way
ANOVA with Bonferroni’s post-test, or
using paired t tests, as appropriate.
Differences were considered significant at P
less than 0.05; n represents the number of
experimental repeats.
Results
Hsp90 Inhibition Protects against
LPS-Mediated HLMVEC
Barrier Dysfunction
HLMVECs were grown on gold electrode
arrays. TER was monitored until successive
constant values were attained, confirming
a confluent monolayer. Cells were then
exposed to vehicle or the Hsp90 inhibitor,
17-AAG (2 mM; Figure 1A) or AUY-922
(2 mM; Figure 1B) for 2 hours, followed by
PBS or LPS (1 EU/ml). LPS decreased TER
values, suggesting increased permeability of
the monolayer. Both 17-AAG and AUY-
922 pretreatment prevented the LPS-
mediated decrease in TER in HLMVECs. In
addition, paracellular permeability across
the HLMVECs was studied using the
transwell assay system. HLMVEC
monolayers grown on a transwell insert
were exposed to vehicle or AUY-922
(2 mM, Figure 1C) for 2 hours, followed by
PBS or LPS (5 EU/ml). LPS increased the
influx of 2M kD FITC-dextran in the basal
media, suggesting increased paracellular
permeability; pretreatment with AUY-922
prevented the LPS-mediated increase in the
influx of 2M kD FITC-dextran, suggesting
that Hsp90 inhibition prevents LPS-





To test whether Hsp90 inhibition can
restore TER that has already been disrupted
by LPS, HLMVEC monolayer were exposed
to PBS or LPS (1 EU/ml), followed 3 hours
later by either 17-AAG or AUY-922 (2 mM).
Post-treatment with either 17-AAG
(Figure 1D) or AUY-922 (Figure 1E)
completely restored the LPS-mediated
decrease in TER.
ROCK Inhibition Protects against
LPS-Mediated Decrease in TER
RhoA signaling, facilitated downstream by
ROCK, is a major pathway of LPS-mediated
inflammation. We used two small-molecule
inhibitors of ROCK (Y27632 and
GSK429286 at 10 mM) to study their effects
on TER and MLC phosphorylation.
HLMVEC monolayers were pretreated with
either vehicle, Y27632 or GSK429286,
followed by either PBS or LPS. TER was
monitored continuously. Y27632 or
GSK429286, alone, had no effect on TER
values (data not shown). However, both
ROCK inhibitors protected HLMVECs
against LPS-mediated decrease in TER
(Figure 2A) suggesting a major role for the
RhoA-ROCK pathway in LPS-mediated
barrier disruption in HLMVECs.
Furthermore, the ROCK inhibitors
provided complete abrogation of LPS-
induced MLC phosphorylation, suggesting
that LPS-mediated MLC phosphorylation is
via the RhoA-ROCK pathway (Figure 2B).
Figure 2. Inhibition of Rho kinase (ROCK) protects against the LPS-mediated decrease in TER. (A) HLMVECs were grown to confluence on ECIS arrays
(8W10E1). Once a constant resistance was attained, the cells were treated with vehicle (0.1% dimethyl sulfoxide [DMSO]), Y27632 (10 mM), or
GSK429286 (10 mM) for 2 hours. LPS (1 EU/ml) was then added as indicated by the arrow and TER values were measured continuously and normalized to
the 0-hour value. Data represent means (6 SEM); n = 4. *P , 0.0001 versus vehicle, #P , 0.0001 versus LPS, ##P , 0.01 versus LPS. (B) HLMVECs
grown to confluence in six-well plates were preincubated with vehicle (0.1% DMSO), Y27632 (10 mM), or GSK429286 (10 mM) for 2 hours, followed
by treatment with 1 EU/ml LPS for 2 hours. Western blot analysis was performed for diphosphorylated myosin light chain (ppMLC) and b-actin.
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Hsp90 Inhibition Suppresses
LPS-MediatedRhoAActivity andNitration
We then tested the hypothesis that Hsp90
inhibition would affect LPS-mediated RhoA
activation and signaling. LPS exposure for 2
hours increased RhoA activity in HLMVECs
and 17-AAG pretreatment attenuated the
LPS-mediated RhoA activation (Figure 3A).
Recently, we demonstrated that RhoA
nitration stimulates its activity
(unpublished data). Therefore, we tested
if 17-AAG pretreatment affected LPS-
induced RhoA nitration as well. HLMVECs
were pretreated with 17-AAG for
2 hours, followed by LPS exposure;
immunoprecipitation of RhoA and
Western blot analysis for nitrotyrosine
and RhoA was then performed (Figure 3B).
LPS increased nitrotyrosine levels of RhoA
and, as shown in the histogram that depicts
fold change in the ratio of nitrated to total
RhoA band densities, 17-AAG completely
blocked the LPS-mediated RhoA nitration
(Figure 3B). Together, the above data
indicate that Hsp90 inhibitors act upstream
of RhoA to block LPS-induced nitration of
RhoA, thereby suppressing its activation.
Hsp90 Inhibition Suppresses
LPS-Mediated MLC Phosphorylation
MLC regulates actin–myosin contractility
and is a known target of the RhoA-ROCK
pathway. We tested the effect of Hsp90
inhibition on LPS-mediated MLC
phosphorylation. LPS induced robust MLC
phosphorylation at both 2 and 4 hours; this
was totally blocked by either 17-AAG
or AUY-922 (Figure 4). However, after
6 hours of LPS exposure, MLC
phosphorylation was absent, suggesting
that MLC phosphorylation is an early
signaling event after LPS addition, and is
not required to maintain LPS-induced
hyperpermeability.
Hsp90 Inhibition Attenuates the
Decrease in TER Caused by
Constitutively Active
RhoA Expression
To investigate whether Hsp90 also functions
downstream of RhoA, we utilized an
adenovirus expressing a constitutively active
form of RhoA (CA-RhoA). HLMVECs
grown on ECIS arrays were exposed to
adenoviruses expressing either GFP or CA-
RhoA for 24 hours. Vehicle or 17-AAG was
then added for another 24 hours. TER was
recorded continuously throughout the
experiment. HLMVECs infected with CA-
RhoA exhibited a gradual decrease in TER
values; however, 17-AAG restored TER to
control values (Figure 5A). Western blot
analysis of MLC phosphorylation
demonstrated that expression of CA-RhoA
increased MLC phosphorylation, and that
17-AAG suppressed the CA-RhoA-induced
MLC phosphorylation (Figure 5B).
Together, the above data suggest that
Hsp90 also plays a significant role
downstream of RhoA in mediating the LPS-





Because LPS induced Rho activity and
signaling, we also studied the effect of RhoA
inhibition on MLC phosphorylation by
overexpressing DN-RhoA. HLMVECs were
infected with adenoviruses expressing either
GFP or DN-RhoA. After 24 hours, cells were
exposed to either PBS or LPS (1 EU/ml) for
2 hours, and Western blot analysis was
performed on cell lysates. Overexpression of
DN-RhoA completely blocked LPS-induced
MLC phosphorylation (Figure 5C),
suggesting that the RhoA-ROCK pathway




We previously reported that LPS-induced
pp60Src phosphorylation and activity in
bovine endothelial cells is suppressed by
Figure 3. Hsp90 inhibition attenuates the LPS-mediated RhoA activity and nitration. (A) HLMVECs were grown in 100-mm dishes. Confluent cells were
treated with 2 mM 17-AAG for 2 hours, followed by LPS (1 EU/ml) for 2 hours. Cells were then lysed and RhoA activity was measured using the G-LISA RhoA
activation assay. Data represent means (6 SEM); n = 4. *, #P , 0.05. (B) HLMVECs were treated as described previously here. Cells were then lysed, RhoA
was immunoprecipitated using anti-RhoA antibody, and then immunoblotting was performed using antibodies against nitrotyrosine and RhoA. Normalized
nitrotyrosine levels are shown. Data represent means (6 SEM); n = 7. *P , 0.05 from vehicle; #P , 0.05 from LPS. IP, immunoprecipitated.
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inhibition of Hsp90 (5). Therefore, we
investigated if SFKs play a role in regulating
RhoA activity and signaling. We first
examined whether inhibition of SFKs
affects LPS-induced RhoA activity.
HLMVECs were pretreated for 2 hours
with vehicle or the SFK inhibitor, PP2
(10 mM), followed by treatment with either
PBS or LPS. After 2 hours of LPS treatment,
RhoA activity was determined in cell
lysates. PP2 pretreatment inhibited LPS-
induced RhoA activity (Figure 6A).
Furthermore, Western blot analysis showed
that PP2 also suppressed LPS-mediated
phosphorylation of MLC (Figure 6B). These
data suggest that LPS induces RhoA
activation and signaling via SFKs.
Discussion
The molecular chaperone, Hsp90, is
involved in a variety of cellular processes
(14). Inhibition of Hsp90, therefore, affects
a broad range of signaling molecules
(14–17, 26). Our laboratory has previously
shown that Hsp90 inhibition prolongs
survival and attenuates inflammation in
mice exposed to lethal doses of LPS (25),
and protects and restores endothelial
hyperpermeability in cultured BPAECs
caused by various proinflammatory agents
(5, 20). However, the mechanisms
responsible for these effects remain
unknown. Because RhoA activation has
been shown to be a major factor in LPS-
induced ALI, we then tested the hypotheses
that hsp90 inhibitors ameliorate LPS-
induced ALI by acting on targets both
upstream and downstream of Rho. To
enhance the translational nature of the
studies, these experiments were performed
on in-house–harvested HLMVECs.
Pretreatment of HLMVEC monolayers
with Hsp90 inhibitors, either 17-AAG or
AUY-922, effectively blocked the LPS-
induced decrease in TER, suggesting that
Hsp90 function is critical in mediating LPS-
induced endothelial barrier disruption. In
addition, the Hsp90 inhibitor, AUY-922,
completely blocked the LPS-induced
transport of 2M kD FITC-dextran across the
HLMVEC monolayer, confirming the TER
findings and suggesting that the effect of
Hsp90 and its inhibitors is primarily on
paracellular permeability. Furthermore,
when Hsp90 inhibitors are added to cells
that already exhibit a decreased TER due to
LPS exposure, barrier function is restored,
suggesting that the sustained disruption of
the endothelial barrier by LPS downstream
signaling also requires functional Hsp90.
Together, the above data indicate that
Hsp90 plays a role in two distinct phases of
LPS-induced barrier disruption: the first
phase involves the early processes wherein
LPS binds the host Toll-like receptor 4
receptor complex and transmits signals that
cause an immediate decrease in TER; and
the second phase, where the barrier
disruption is maintained.
LPS-mediated barrier disruption is
associated with ROCK-dependent
regulation of the actin cytoskeleton.
Inhibitors of ROCK attenuate ROCK-
mediated actin cytoskeleton changes (12, 27,
28). For example, inhibition of ROCK by
fasudil attenuated LPS-induced
hyperpermeability in guinea pigs (29). In
addition, the ROCK inhibitor, Y27632,
effectively blocked permeability caused by
the gram-negative bacteria, Pseudomonas
aeruginosa (30), but did not attenuate
airway microvascular leakage induced by
leukotriene D(4) or histamine (31). In
contrast, in a recent study, pretreatment
with the ROCK inhibitor, Y27632, failed to
inhibit the LPS-induced hyperpermeability
of commercially available HLMVECs (12).
In light of this conflicting evidence, we
evaluated the effect of ROCK inhibition on
in-house–isolated and –characterized
HLMVECs. Pretreatment with either of two
ROCK inhibitors, Y27632 or GSK429286,
at concentrations significantly higher (10
mΜ) and for much longer times (2 h) than
those used in a previous study (0.5 and
5 mM for 15 min) (7), provided partial, but
significant, protection against LPS-induced
disruption of HLMVEC barrier function.
These data suggest a major role for ROCK
in the early phase of LPS-induced barrier
disruption in human lung microvascular
cells. Because Hsp90 also plays a crucial
role in the early phase of LPS-mediated
barrier disruption, the data point to
a strong correlation between Hsp90 and
ROCK-dependent actin cytoskeletal
changes.
ROCK is a major effector kinase for the
small-GTPase RhoA (32), the activity of
which is induced by exposure of endothelial
cells to LPS. Furthermore, inactivation of
RhoA has been shown to improve barrier
function (33, 34). Other studies have shown
that vascular endothelial growth factor–
and thrombin-induced RhoA activity was
inhibited by the Hsp90 inhibitor
geldanamycin (35, 36). S.M.B. and
colleagues recently discovered that RhoA
nitration stimulates RhoA activity
(unpublished data). Therefore, we sought
to evaluate whether Hsp90 inhibition by
Figure 4. Inhibition of Hsp90 suppresses the LPS-induced MLC phosphorylation. HLMVECs were
grown in six-well plates. Confluent cells were treated with vehicle, 2 mM 17-AAG, or 2 mM AUY-922
for 2 hours, followed by exposure to LPS (1 EU/ml) for 2, 4, or 6 hours. Cells were then lysed and
Western blot analysis was performed using antibodies against ppMLC and MLC. Densitometric
analysis was performed, and the ratio of ppMLC to MLC was plotted. Data represent means (6 SEM);
n = 3. *P , 0.05 versus vehicle; #P , 0.05 versus 2-hour LPS alone treatment; ##P , 0.05 versus
4-hour LPS alone treatment.
ORIGINAL RESEARCH
Joshi, Dimitropoulou, Thangjam, et al.: Hsp90-Rho in Endothelial Hyperpermeability 175
17-AAG affects LPS-induced RhoA
nitration and activation in HLMVECs. Our
data demonstrate that LPS stimulated both
RhoA tyrosine nitration and RhoA activity
in HLMVECs. Furthermore, pretreatment
with 17-AAG prevented both the LPS-
induced RhoA activity and the LPS-
mediated RhoA tyrosine nitration. This
inhibition of RhoA activity also suppresses
ROCK-dependent actin cytoskeleton
changes and MLC phosphorylation.
MLC is a known downstream target of
ROCK, and phosphorylation of MLC by
ROCK causes remodeling of the actin
cytoskeleton, leading to endothelial
hyperpermeability (10, 12, 37, 38). In
agreement with the studies cited previously
here, LPS-induced MLC phosphorylation in
HLMVECs is inhibited by both ROCK
inhibitors, Y27632 and GSK429286.
Furthermore, pretreatment with Hsp90
inhibitors completely blocked LPS-induced
MLC phosphorylation, which supports our
finding that hsp90 inhibitors block LPS-
induced RhoA activation. Moreover, when
HLMVECs were infected with adenovirus
carrying DN form of RhoA, LPS-induced
MLC phosphorylation was completely
blocked. These data demonstrate that
Hsp90 inhibitors block LPS-induced and
RhoA-mediated signaling to MLC, and
support the hypothesis that Hsp90 regulates
key signaling steps upstream of RhoA.
Therefore, we then investigated the role of
Hsp90 downstream of RhoA, and tested the
hypothesis that barrier disruption induced
by the expression of CA-RhoA could be
restored by Hsp90 inhibition. 17-AAG
restored barrier function and attenuated
MLC phosphorylation in cells expressing
CA-RhoA, suggesting a barrier-disruptive
role for Hsp90 downstream of RhoA as
well. The precise target of Hsp90 regulation
of MCL phosphorylation downstream of
RhoA remains unclear. Recently, however,
Figure 5. 17-AAG restores LPS-mediated hyperpermeability caused by constitutively active RhoA (CA-RhoA). (A) HLMVECs were grown on ECIS
arrays. Subconfluent HLMVECs were infected with adenoviruses expressing either GFP or CA-RhoA (50 multiplicity of infection [MOI]). After 24 hours,
17-AAG was added to a final concentration of 2 mM. TER values were measured continuously and normalized to time = 0 hours. Data represent means
(6 SEM); n = 3. *P , 0.001 versus GFP, #P , 0.001 versus CA-RhoA 1 17-AAG. (B) Subconfluent HLMVECs were exposed to adenoviruses expressing
either GFP (50 MOI) or CA-Rho (50 MOI). After 24 hours, transduction efficiency greater than 90% was noted by observing GFP-expressing cells.
Cells were treated either with vehicle (0.1% DMSO) or with 2 mM 17-AAG for another 24 hours. Cell lysates were prepared and immunoblotted for ppMLC
and MLC. Densitometric analysis was performed using Imagequant 5.1 and shown as fold change from vehicle. Data represent means (6 SEM); n = 4.
*P , 0.05. (C) Cells were grown on six-well plates. Subconfluent HLMVECs were infected with adenoviruses expressing either GFP or dominant-negative
(DN)-RhoA (500 MOI). After 24 hours, cells were exposed to LPS (0–5 EU/ml) for 2 hours, lysed, and immunoblotted using antibodies against
ppMLC, MLC, and RhoA. Densitometric analysis was performed, and the ratio of ppMLC to MLC was plotted. Data represent mean (6 SEM); n = 3.
*P , 0.05 from vehicle; #P , 0.05 from LPS.
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we demonstrated that 17-AAG prevents
transforming growth factor-b–induced
Hsp27 phosphorylation, and that Hsp27 is
a client protein of Hsp90, in BPAECs (3).
Hsp27 may thus be a possible Hsp90-sensitive
target of RhoA downstream signaling.
Upstream of RhoA, we hypothesized
that the kinase pp60Src, an Hsp90 client
protein, mediates the LPS-induced RhoA
activation and signaling. SFKs have been
shown to contribute to endothelial cell
hyperpermeability (6–8, 14). Inhibition of
SFKs by PP2 or knockdown of SFK
members, pp60Src, YES, or FYN, partially
protected against LPS-mediated barrier
disruption (8). In addition, expression of
constitutively active pp60Src has been
shown to decrease endothelial barrier
function (39). Therefore, we tested whether
inhibition of SFKs would affect the LPS-
mediated RhoA activation. Our data clearly
show that pretreatment with the SFK
inhibitor, PP2, completely blocked the LPS-
induced RhoA activation and suppressed
the LPS-induced MLC phosphorylation in
HLMVECs, suggesting that LPS-mediated
RhoA activation is mediated by SFK, and
raising the distinct possibility that Hsp90
inhibitors block RhoA activity by inhibiting
the activation of SFK.
We have previously shown that
inhibition of Hsp90 by 17-AAG prolongs
survival, attenuates lung injury, and
decreases neutrophil infiltration in a murine
model of sepsis (25). Studies have also
shown similar protective effect in the lung
when mice are pretreated with either
tyrosine kinase inhibitor (40–42), SFK
inhibitor (8), RhoA inhibitor (40), or
ROCK inhibitors (43, 44), followed by LPS
exposure. In addition, down-regulation of
SFK also reduces LPS-mediated endothelial
hyperpermeability (8). Collectively, the data
Figure 6. Inhibition of Src family kinases (SFKs) attenuates the LPS-mediated RhoA activity and MLC phosphorylation. HLMVECs were grown to
confluence in 60-mm dishes, treated with either vehicle (0.1% DMSO) or PP2 (10mM) for 2 hours, and then with LPS (2 EU/ml) for 90 minutes (A). RhoA
activity was measured using the G-LISA RhoA activation assay. Data represent means (6 SEM); n = 4. *P , 0.05 from vehicle, #P , 0.05 from LPS. (B)
Western blot analysis was performed for ppMLC and MLC. Data represent means (6 SEM); n = 3. *P , 0.05 from vehicle, #P , 0.05 from LPS.
Figure 7. Proposed regulation of LPS-mediated of Rho activation and signaling by Hsp90. LPS induces
activation of Rho and its downstream effector kinase, ROCK, leading to MLC phosphorylation and
endothelial hyperpermeability. Inhibition of Hsp90 prevents LPS-induced Rho activation and signaling by
inhibiting pp60Src activity. In addition, downstream of Rho, inhibition of Hsp90 attenuates MLC
phosphorylation, indicating a role of Hsp90 downstream of Rho. EC, endothelial cell.
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support the notion that Hsp90 inhibition
prevents LPS-mediated barrier dysfunction
by suppressing SFK-mediated RhoA-ROCK
activation and signaling (Figure 7).
Endothelial barrier dysfunction leads to
a cascade of cytokine release resulting in
systemic inflammation (1, 45, 46). Current
therapeutic strategy of broad-spectrum
antibiotics (47) and anti-cytokine
antibodies (48) do not affect the underlying
molecular machinery involved. The ATP-
dependent molecular chaperone, Hsp90,
regulates the stability and activity of over
200 proteins, including a number of protein
kinases and transcription factors that are
directly involved in inflammation and
barrier protection (5, 14, 19, 20, 25, 49).
These data, in combination with our
studies, indicate that Hsp90 inhibition
provides a multitargeted therapy that can
play a major role in diseases affecting
endothelial function, and support the
growing belief that multitargeted rather
than single-target approaches hold greater
therapeutic promise (50). n
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